While the Nasdaq was falling 5.5%, three healthcare investors put $50 million into a company that takes a patient’s skin cells, converts them into brain cells, and implants them to treat Parkinson’s disease. The therapy worked in its first clinical trial.
You read this morning that OrbiMed Advisors, director Peter Thompson, and Arch Venture Partners invested a combined $50 million in Aspen Neuroscience on November 2. Tonight, let’s look at what they bought into.
Three questions I’ll answer
| — |
How does a company turn skin cells into brain cells — and why does it matter for Parkinson’s? |
| — |
What did the first clinical trial actually show — and how did patients respond? |
| — |
Why did three separate investors commit $50 million on the same day? |
This is the kind of science the smart money prices before the headlines reach it. I’ll walk you through the data. ↓
|
|
|
Skin Cells to Brain Cells
Aspen Neuroscience (ticker: ASPE) is a clinical-stage biotech based in San Diego developing what may be the most literal form of personalized medicine in existence. The company takes a small skin biopsy from a Parkinson’s patient, converts those skin cells into induced pluripotent stem cells — cells reprogrammed to behave like embryonic stem cells — and then transforms those into dopaminergic neuron precursors, the exact type of brain cell that dies in Parkinson’s disease. A surgeon then implants the new cells into the patient’s brain using MRI guidance. Because the cells come from the patient’s own body, no immune-suppression drugs are needed.
THE CLINICAL DATA
In March 2026, Aspen presented 12-month results from its Phase 1/2a ASPIRO trial, the first-in-human test of this approach. Fifteen patients have been dosed. The results stood out.
|
Additional “Good ON Time” Per Day
|
~2 hours
|
|
Motor Score Improvement (OFF state)
|
−15.5 pts
|
|
Quality of Life Improvement (low dose)
|
+51.6%
|
|
Serious Surgical Adverse Events
|
Zero
|
PET imaging confirmed the transplanted cells survived and successfully grafted into the brain. No severe graft-induced dyskinesia — involuntary movements caused by the new cells — was observed. Aspen plans to begin a Phase 3 trial in the second half of 2027, and it filed for an IPO in October seeking $100 million.
WHY THREE INVESTORS ON ONE DAY
OrbiMed Advisors, a healthcare-focused fund managing over $40 billion, put in $15 million. Director Peter Thompson, already a 10% owner, added another $15 million. Arch Venture Partners, a biotech venture fund with a record of early-stage bets on companies that reached FDA approval, committed $20 million. Three parties, $50 million, one day. When investors with that depth of scientific due diligence commit at that scale simultaneously, they have seen the data and formed a view on where this program is headed.
NATE’S TAKE
In 25 years I have tracked thousands of insider purchases. Very few stop me mid-sentence the way this one did. A company that takes a skin biopsy, reprograms the cells, grows them into the exact neurons Parkinson’s destroys, and implants them into the brain — and it worked in the first 15 patients, with no immune suppression required. Three of the most respected names in healthcare investing put $50 million behind that data on a day the rest of the market lost $2.2 trillion. The market was pricing AI regulation risk. OrbiMed, Thompson, and Arch Venture were pricing a one-time cell therapy for a disease that affects 10 million people worldwide. Those are two very different bets on the future, and only one of them requires a new Congress to resolve.
— Nate Fowler
After the Bell · Evening Special Edition
|
|
Tidak ada komentar:
Posting Komentar